Skip to main content
. 2011 May;55(5):1896–1905. doi: 10.1128/AAC.01756-10

Table 3.

Details of 23 ACME arc-positive MRSA isolates

MRSA description/source Isolate no. Yr of isolation Isolate source Antimicrobial resistance patterna ST SCCmec type spa type dru type PFT DNA microarray groupc
PVL locus positive ML224 2003 Skin abscess AMP, CAD, CIP, ERY, KAN, NEO 8 IVa t008 dt9g 99023 ST8-MRSA-IV (a)
M05/0199 2005 Pneumonia (USA travel) AMP, CIP, ERY, KAN, NEO 8 IVa t008 dt9g 99025 ST8-MRSA-IV (a)
M05/0259 2005 Face infection AMP, ERY, KAN, NEO 8 IVa t008 dt9g 99023 ST8-MRSA-IV (a)
M05/0028 2005 Buttock abscess AMI, AMP, ERY, KAN, NEO 8 IVa t008 dt9g 99023 ST8-MRSA-IV (a)
M04/0266 2005 Inguinal lymphadenitis AMI, AMP, ERY, KAN, NEO 8 IVa t4306 dt9g 99017 ST8-MRSA-IV (a)
M05/0060 2005 Skin scalp abscess AMI, AMP, CHL, ERY, KAN, LIN, NEO 8 IVa t008 dt9g 99024 ST8-MRSA-IV (b)
M05/0100 2005 Staff screening AMP, CIP, ERY 8 IVa t008 dt9z 99023 ST8-MRSA-IV (c)
E1401 2003 Blood/bacteremia AMP, ERY 22 IVa t2480 dt10am 01003 ST22-MRSA-IV (a)
Four-ward study M08/0119 2008 Nasal AMP, CAD, CIP, ERY, KAN, LIN, MUP, TOB 22 IVh t3185 dt10o 01154 ST22-MRSA-IV (b)
M08/0121 2008 Air AMP, CAD, CIP, ERY, KAN, LIN, MUP, TOB 22b IVh t3185 dt10o 01154 ST22-MRSA-IV (b)
M08/0122 2008 Air AMP, CAD, CIP, ERY, GEN, KAN, LIN, MUP, TOB 22b IVh t3185 dt10o 01154 ST22-MRSA-IV (b)
M08/0123 2008 Air AMP, CAD, CIP, ERY, GEN, KAN, LIN, MUP, TOB 22b IVh t3185 dt10o 01154 ST22-MRSA-IV (b)
M08/0124 2008 Air AMP, CAD, CIP, ERY, GEN, KAN, LIN, MUP, TOB 22b IVh t3185 dt10o 01154 ST22-MRSA-IV (b)
M08/0126 2008 Mattress AMP, CAD, CIP, ERY, GEN, KAN, LIN, MUP, TOB 22b IVh t3185 dt10o 01154 ST22-MRSA-IV (b)
M08/0129 2008 Bathroom floor AMP, CAD, CIP, ERY, GEN, KAN, LIN, MUP, TOB 22b IVh t3185 dt10o 01154 ST22-MRSA-IV (b)
M08/0131 2008 Air AMP, CAD, CIP, ERY, GEN, KAN, LIN, MUP, TOB 22b IVh t3185 dt10o 01154 ST22-MRSA-IV (b)
M08/0132 2008 Air AMP, CAD, CIP, ERY, GEN, KAN, LIN, MUP, TOB 22b IVh t3185 dt10o 01154 ST22-MRSA-IV (b)
M08/0133 2008 Air AMP, CAD, CIP, ERY, GEN, KAN, LIN, MUP, TOB 22b IVh t3185 dt10o 01154 ST22-MRSA-IV (b)
M08/0135 2008 Mattress AMP, CAD, CIP, ERY, GEN, KAN, LIN, MUP, TOB 22b IVh t3185 dt10o 01154 ST22-MRSA-IV (b)
M08/0161 2008 Bathroom floor AMP, CAD, CIP, ERY, GEN, KAN, LIN, MUP, TOB 22b IVh t3185 dt10o 01154 ST22-MRSA-IV (b)
M08/0128 2008 Air AMP, CAD, CIP, ERY, GEN, KAN, LIN, MUP, TOB 22b IVh t3185 dt10o 01154 ST22-MRSA-IV (c)
M08/0134 2008 Air AMP, CAD, CIP, ERY 22 IVh t3185 dt10o 01154 ST22-MRSA-IV (d)
M08/0136 2008 Mattress AMP, CAD, CIP, ERY 22b IVh t3185 dt10o 01154 ST22-MRSA-IV (d)
a

Antimicrobials tested included amikacin (AMI), ampicillin (AMP), cadmium acetate (CAD), chloramphenicol (CHL), ciprofloxacin (CIP), erythromycin (ERY), ethidium bromide, fusidic acid, gentamicin (GEN), kanamycin (KAN), lincomycin (LIN), mercuric chloride, mupirocin (MUP), neomycin (NEO), phenyl mercuric acetate, rifampin, spectinomycin (SPC), streptomycin, sulfonamide, tetracycline, tobramycin (TOB), trimethoprim, and vancomycin.

b

ST assigned by DNA microarray analysis using the StaphyType kit (Alere Technologies). Other STs were also determined by MLST.

c

Isolates within each ST-SCCmec type (ST8-MRSA-IV or ST22-MRSA-IV) were assigned to DNA microarray groups on the basis of the presence of a unique combination of virulence and/or antimicrobial resistance genes. DNA microarray results are shown in Table 4.